These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 21050361)

  • 1. The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers.
    Makhlin I; Zhang J; Long CJ; Devarajan K; Zhou Y; Klein-Szanto AJ; Huang M; Chernoff J; Boorjian SA
    BJU Int; 2011 Jul; 108(2 Pt 2):E84-90. PubMed ID: 21050361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma.
    Hansel DE; Platt E; Orloff M; Harwalker J; Sethu S; Hicks JL; De Marzo A; Steinle RE; Hsi ED; Theodorescu D; Ching CB; Eng C
    Am J Pathol; 2010 Jun; 176(6):3062-72. PubMed ID: 20395440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation.
    Seront E; Pinto A; Bouzin C; Bertrand L; Machiels JP; Feron O
    Br J Cancer; 2013 Sep; 109(6):1586-92. PubMed ID: 23989949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapamycin enhances growth inhibition on urothelial carcinoma cells through LKB1 deficiency-mediated mitochondrial dysregulation.
    Whang YM; Kim MJ; Cho MJ; Yoon H; Choi YW; Kim TH; Chang IH
    J Cell Physiol; 2019 Aug; 234(8):13083-13096. PubMed ID: 30549029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma.
    Hirashima K; Baba Y; Watanabe M; Karashima RI; Sato N; Imamura Y; Nagai Y; Hayashi N; Iyama KI; Baba H
    Br J Cancer; 2012 Feb; 106(5):876-82. PubMed ID: 22333597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Downstream Genes of the mTOR Pathway that Predict Recurrence and Progression in Non-Muscle Invasive High-Grade Urothelial Carcinoma of the Bladder.
    Jin S; Chang IH; Kim JW; Whang YM; Kim HJ; Hong SA; Lee TJ
    J Korean Med Sci; 2017 Aug; 32(8):1327-1336. PubMed ID: 28665070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rictor-dependent AKT activation and inhibition of urothelial carcinoma by rapamycin.
    Wu MJ; Chang CH; Chiu YT; Wen MC; Shu KH; Li JR; Chiu KY; Chen YT
    Urol Oncol; 2012; 30(1):69-77. PubMed ID: 20207175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo and in vitro effects of RAD001 on bladder cancer.
    Vasconcelos-Nóbrega C; Pinto-Leite R; Arantes-Rodrigues R; Ferreira R; Brochado P; Cardoso ML; Palmeira C; Salvador A; Guedes-Teixeira CI; Colaço A; Palomino LF; Lopes C; Santos L; Oliveira PA
    Urol Oncol; 2013 Oct; 31(7):1212-21. PubMed ID: 22169072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temsirolimus improves cytotoxic efficacy of cisplatin and gemcitabine against urinary bladder cancer cell lines.
    Pinto-Leite R; Arantes-Rodrigues R; Ferreira R; Palmeira C; Colaço A; Moreira da Silva V; Oliveira P; Lara Santos L
    Urol Oncol; 2014 Jan; 32(1):41.e11-22. PubMed ID: 24035472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphorylated p70S6K in noninvasive low-grade urothelial carcinoma of the bladder: correlation with tumor recurrence.
    Kim SJ; Kim JH; Jung HS; Lee TJ; Lee KM; Chang IH
    Asian J Androl; 2014; 16(4):611-7. PubMed ID: 24625880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
    Liu J; Zhang L; Zhang X; Xing X
    J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined effect of rapamycin and cisplatin on survival of Hep-2 cells in vitro.
    Lei W; Jia T; Su Z; Wen W; Zhu X
    Oncol Res; 2009; 18(2-3):73-81. PubMed ID: 20066897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells.
    Chiong E; Lee IL; Dadbin A; Sabichi AL; Harris L; Urbauer D; McConkey DJ; Dickstein RJ; Cheng T; Grossman HB
    Clin Cancer Res; 2011 May; 17(9):2863-73. PubMed ID: 21415218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations of mTOR and PTEN protein expression in schistosomal squamous cell carcinoma and urothelial carcinoma.
    Makboul R; Refaiy A; Abdelkawi IF; Hameed DA; Elderwy AA; Shalaby MM; Merseburger AS; Hussein MR
    Pathol Res Pract; 2016 May; 212(5):385-92. PubMed ID: 26916953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P70S6K and Elf4E dual inhibition is essential to control bladder tumor growth and progression in orthotopic mouse non-muscle invasive bladder tumor model.
    Chi BH; Kim SJ; Seo HK; Seo HH; Lee SJ; Kwon JK; Lee TJ; Chang IH
    J Korean Med Sci; 2015 Mar; 30(3):308-16. PubMed ID: 25729255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial Carcinoma.
    Ho IL; Kuo KL; Liu SH; Chang HC; Hsieh JT; Wu JT; Chiang CK; Lin WC; Tsai YC; Chou CT; Hsu CH; Pu YS; Shi CS; Huang KH
    Sci Rep; 2015 Nov; 5():16948. PubMed ID: 26592553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer.
    Mansure JJ; Nassim R; Chevalier S; Rocha J; Scarlata E; Kassouf W
    Cancer Biol Ther; 2009 Dec; 8(24):2339-47. PubMed ID: 20061787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Huaier aqueous extract sensitizes cells to rapamycin and cisplatin through activating mTOR signaling.
    Hu Z; Yang A; Fan H; Wang Y; Zhao Y; Zha X; Zhang H; Tu P
    J Ethnopharmacol; 2016 Jun; 186():143-150. PubMed ID: 27045863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allyl-, Butyl- and Phenylethyl-Isothiocyanate Modulate Akt-mTOR and Cyclin-CDK Signaling in Gemcitabine- and Cisplatin-Resistant Bladder Cancer Cell Lines.
    Rutz J; Maxeiner S; Grein T; Sonnenburg M; Khadir SE; Makhatelashvili N; Mann J; Xie H; Cinatl J; Thomas A; Chun FK; Haferkamp A; Blaheta RA; Tsaur I
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.